Walker (ID 0118460) v. Easter

CourtDistrict Court, D. Kansas
DecidedFebruary 12, 2020
Docket5:17-cv-03176
StatusUnknown

This text of Walker (ID 0118460) v. Easter (Walker (ID 0118460) v. Easter) is published on Counsel Stack Legal Research, covering District Court, D. Kansas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Walker (ID 0118460) v. Easter, (D. Kan. 2020).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF KANSAS

JAMES K. WALKER,

Plaintiff,

vs. Case No. 17-03176-EFM-ADM

JEFF EASTER and HAROLD STOPP, D.O.,

Defendants.

MEMORANDUM AND ORDER

Proceeding pro se, Plaintiff James K. Walker filed this suit alleging that he received inadequate medical care while incarcerated at Sedgwick County Adult Detention Facility (“SCADF”) between June 1, 2017, and February 28, 2018. Defendants Sheriff Jeff Easter and Harold Stopp, D.O., are the only remaining Defendants in this case. Against Dr. Stopp, Walker asserts claims of medical negligence and deliberate indifference to serious medical need under the Eighth and Fourteenth Amendments. Against Sheriff Easter, Walker seeks an order from the Court ordering Sheriff Easter to pay compensatory and punitive damages. Pending before the Court is Defendants’ Motion for Summary Judgement (Doc. 109) and Walker’s Motion for Summary Judgment (Doc. 111). For the reasons set forth below, the Court grants Defendants’ motion and denies Walker’s motion. I. Factual and Procedural Background A. Local Rules for Summary Judgment The required rules for summary judgment motions in the District of Kansas are set forth in D. Kan. Rule 56.1. Subsection (b) addresses memorandums opposing summary judgment. A memorandum in opposition must first state the material facts as to which the opposing party

contends there is a genuine dispute.1 Each fact in dispute must be numbered by paragraph, refer to the number of the movant’s fact in dispute, and refer to the record with particularity.2 Additionally, the party opposing summary judgment must set forth any additional facts it relies on supported by references to the record.3 In this case, Walker filed several documents in response to Defendants’ Motion for Summary Judgment. He filed a “Motion Plaintiffs’ Opposition to Defendants’ Summary Judgment Motion,” which is handwritten and one page. Attached as exhibits to this document are (1) “Plaintiffs’ Brief in Support of Opposition of Defendants’ Summary Judgment Motion;” (2) Plaintiff’s Affidavit in Support of Opposition to Defendants’ Motion for Summary Judgment;”

and (3) “Plaintiffs’ Statement of Disputed Factual Issues in Support of Opposition to Defendants’ Summary Judgment Motion.” Defendants argue that Walker has not responded to Defendants’ Statement of Uncontroverted Facts. But, Walker’s Affidavit makes specific reference to the page and paragraph number of the statements set forth in Dr. Stopp’s Affidavit. Defendants have extensively cited Dr.

1 D. Kan. Rule 56.1(b)(1). 2 Id. 3 D. Kan. Rule 56.1(b)(2). Stopp’s Affidavit in their Statement of Uncontroverted Facts. Therefore, the Court will look to Walker’s Affidavit in determining which facts remain uncontroverted. Defendants also point out that none of the documents Walker filed in response to Defendants’ motion includes a section titled “statement of additional material facts.” However, Walker’s Brief in Support of Opposition contains 35 numbered paragraphs that contain a mixture

of alleged facts, conclusory statements, and legal arguments. Some of these facts are supported by Walker’s affidavit. Defendants have responded to the numbered statements in Walker’s Opposition Brief as though it were an additional statement of facts. Therefore, to the extent these facts are supported by Walker’s affidavit, the Court will consider them in this Order. B. Facts 1. Walker’s Medical Treatment While at SCADF Plaintiff was incarcerated at SCADF from August 15, 2015, to February 28, 2018. Sometime before June 1, 2017, Plaintiff contracted a skin condition and a suspected DVT4 in his leg. For the skin rash he took Triamcinolone 0.1% cream, and Thera-Derm lotion, and for the

DVT, he took a blood thinner called warfarin (sold under the brand name Coumadin). Periodically, he would have labs taken to test his INR5 and Prothrombin Time (PT). Because he was taking Coumadin, the lab reports would often show his INR level as “high” compared to the reference range. The goal, however, was to keep him in the “therapeutic” range.

4 The Court assumes “DVT” stands for deep vein thrombosis. 5 Defendants have not informed the Court what “INR” means. According to the health encyclopedia from the University of Rochester Medical Center, “INR” is the abbreviation for “international normalized ratio.” It is a blood test that looks to see how well blood clots. See https://www.urmc.rochester.edu/encyclopedia/content.aspx?contenttypeid=167&contentid=international_normalized _ratio (last visited Jan. 30, 2020). In June 2017, the outside pharmacy sent DermaDaily instead of Thera-Derm for Walker to use. Dr. Stopp, one of Plaintiff’s attending physicians at SCADF, did not order DermaDaily and did not know why the pharmacy sent that lotion instead of Thera-Derm. On June 17, 2017, Walker signed a document stating that he understood the instructions for DermaDaily, which included applying it in the morning as needed. This form is part of the KOP (“Keep on Person”) program,

which if signed authorizes an inmate to keep the medications identified and provided to them on their person. On July 25, 2017, Walker reported to sick call that he was having an allergic reaction to the lotion he was using. This is Walker’s first documented complaint regarding DermaDaily. He had a large red rash on his abdomen and right leg. Walker reported that he was not getting the right lotion. One of the sick call nurses called the pharmacy tech, who stated that Thera-Derm and DermaDaily are the same medication. The nurse noted that she would call the patient back the next day to discuss other cream options. Dr. Stopp, however, noted that the patient “needs a different cream for rash on trunk and extremities. This is allergic to current cream. Will order

Theraderm [sic].” Dr. Stopp also ordered Tramadol for Walker’s pain. On July 26, Dr. Stopp ordered an antihistamine to treat Walker’s rash. Additionally, Walker’s INR and PT levels were checked and were in therapeutic range. His next INR was scheduled for August. On July 28, the nurse followed up with the pharmacy, noting that the Thera-Derm had not arrived. She refaxed an order from July 20 and wrote “Please DO NOT send Derma daily [sic]. Please send Thera-Derm.” She also called the pharmacy tech, who said that the cream would arrive the next day. On July 31, Dr. Stopp noted that Thera-Derm was ordered, and that Walker signed the KOP document showing he reviewed the instructions for Thera-Derm. Dr. Stopp understood this to mean that Walker received the Thera-Derm on or about this date. Walker, however, denies that he received it. Walker reported to sick call on August 1, complaining of a painful rash on his arms, face,

and left side of the abdomen. Dr. Stopp examined Walker and entered a new order for a steroid named Prednisone. Three days later, Walker presented to Dr. Stopp with the rash on his lower extremities, abdomen, and arms. Dr. Stopp concluded that Walker had dermatitis and told him to continue the Prednisone and Thera-Derm. He also ordered Walker to use Vaseline. The next day, on August 5, Dr. Stopp ordered a bilateral ultrasound to the lower extremities to rule out DVT. From August 12 to August 29, Plaintiff was examined by a physician assistant (“PA”). She continued to treat the rash with Prednisone, and her notes state that under this treatment, the rash markedly improved. As of August 19, Walker still had not received the Thera-Derm. The PA discussed this issue with the medical assistant, who contacted the pharmacy to help resolve the

issue. On August 21, Walker signed the KOP form indicating he received instructions for the Thera-Derm, and on August 25 for the petroleum jelly. On August 28, lab results showed Plaintiff’s INR to be six, which is a “critical” level, rather than a “therapeutic” level.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Estelle v. Gamble
429 U.S. 97 (Supreme Court, 1976)
Helling v. McKinney
509 U.S. 25 (Supreme Court, 1993)
Adler v. Wal-Mart Stores, Inc.
144 F.3d 664 (Tenth Circuit, 1998)
Perkins v. Kansas Department of Corrections
165 F.3d 803 (Tenth Circuit, 1999)
Mitchell v. City of Moore
218 F.3d 1190 (Tenth Circuit, 2000)
Ledbetter v. City of Topeka, KS
318 F.3d 1183 (Tenth Circuit, 2003)
Lifewise Master Funding v. Telebank
374 F.3d 917 (Tenth Circuit, 2004)
Prairie Band Potawatomi Nation v. Wagnon
476 F.3d 818 (Tenth Circuit, 2007)
Self v. Oliva
439 F.3d 1227 (Tenth Circuit, 2006)
Kay v. Bemis
500 F.3d 1214 (Tenth Circuit, 2007)
Southwest Stainless, LP v. Sappington
582 F.3d 1176 (Tenth Circuit, 2009)
Kannady v. City of Kiowa
590 F.3d 1161 (Tenth Circuit, 2010)
Nahno-Lopez v. Houser
625 F.3d 1279 (Tenth Circuit, 2010)
Buell Cabinet Company, Inc. v. Sudduth
608 F.2d 431 (Tenth Circuit, 1979)
Donald Frohmader v. Deputy D. Wayne
958 F.2d 1024 (Tenth Circuit, 1992)
Farmer v. Brennan
511 U.S. 825 (Supreme Court, 1994)
Bacon v. Mercy Hosp. of Ft. Scott
756 P.2d 416 (Supreme Court of Kansas, 1988)

Cite This Page — Counsel Stack

Bluebook (online)
Walker (ID 0118460) v. Easter, Counsel Stack Legal Research, https://law.counselstack.com/opinion/walker-id-0118460-v-easter-ksd-2020.